Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial. Ann Oncol 2020 May 25. pii: S0923-7534(20)39833.
PMID: 32464281